Mike Kratky
Stock Analyst at Leerink Partners
(3.43)
# 921
Out of 4,876 analysts
29
Total ratings
47.62%
Success rate
30.69%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Initiates: Outperform | $118 | $106.53 | +10.77% | 1 | Jun 16, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $86.02 | +27.88% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $15.07 | +85.80% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $11.73 | +2.30% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $86.33 | +0.78% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $132.41 | +48.78% | 2 | Sep 10, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $256.43 | +2.56% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $18.94 | +137.59% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $10.71 | +105.51% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $313.08 | -41.23% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $41.73 | +0.65% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $533.71 | -35.92% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $78.21 | -4.10% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $56.91 | -34.99% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $10.50 | -14.29% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $3.42 | +1,361.99% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.25 | +3,500.00% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $300.75 | +4.74% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $44.12 | -29.74% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $16.10 | -13.04% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $14.33 | +179.13% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $8.43 | +4,455.16% | 1 | Aug 11, 2022 |
Boston Scientific
Jun 16, 2025
Initiates: Outperform
Price Target: $118
Current: $106.53
Upside: +10.77%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $86.02
Upside: +27.88%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $15.07
Upside: +85.80%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $11.73
Upside: +2.30%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $86.33
Upside: +0.78%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $132.41
Upside: +48.78%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $256.43
Upside: +2.56%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $18.94
Upside: +137.59%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $10.71
Upside: +105.51%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $313.08
Upside: -41.23%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $41.73
Upside: +0.65%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $533.71
Upside: -35.92%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $78.21
Upside: -4.10%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $56.91
Upside: -34.99%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $10.50
Upside: -14.29%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $3.42
Upside: +1,361.99%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.25
Upside: +3,500.00%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $300.75
Upside: +4.74%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $44.12
Upside: -29.74%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $16.10
Upside: -13.04%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $14.33
Upside: +179.13%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $8.43
Upside: +4,455.16%